Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

52.0%

13 terminated/withdrawn out of 25 trials

Success Rate

40.9%

-45.6% vs industry average

Late-Stage Pipeline

20%

5 trials in Phase 3/4

Results Transparency

67%

6 of 9 completed trials have results

Key Signals

6 with results10 terminated

Enrollment Performance

Analytics

Phase 1
13(52.0%)
Phase 2
7(28.0%)
Phase 3
4(16.0%)
Phase 4
1(4.0%)
25Total
Phase 1(13)
Phase 2(7)
Phase 3(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT01186328Phase 1Terminated

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Role: collaborator

NCT00549848Phase 3Completed

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Role: collaborator

NCT01295697Phase 1Terminated

Study of EZN-2208 Pediatric Patients With Solid Tumors

Role: lead

NCT01036113Phase 2Terminated

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Role: lead

NCT01656382Phase 4Withdrawn

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

Role: collaborator

NCT00973752Phase 2Completed

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Role: collaborator

NCT00750737Phase 3Completed

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

Role: collaborator

NCT00523939Phase 2Terminated

DepoCyt for Active Lymphomatous or Leukemic Meningitis

Role: collaborator

NCT01337518Phase 1Suspended

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Role: lead

NCT00080002Phase 2Terminated

Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction

Role: lead

NCT00079950Phase 2Suspended

Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma

Role: lead

NCT00520325Phase 1Withdrawn

A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

Role: lead

NCT00886496Phase 1Withdrawn

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Role: lead

NCT00515788Phase 1Terminated

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Role: collaborator

NCT00890656Phase 2Completed

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Role: collaborator

NCT00388999Phase 1Completed

Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant

Role: lead

NCT00931840Phase 2Unknown

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Role: lead

NCT00415311Phase 1Terminated

A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.

Role: lead

NCT00466583Phase 1Completed

Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma

Role: lead

NCT00520390Phase 1Completed

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Role: lead